PLGA Nanoparticles – Bridging the Gap from R&D to GMP

By Fortis Life Sciences

While the bulk polymer PLGA is approved by both the Food and Drug Administration (FDA) and European Medicine Agency (EMA) and is listed in the US Pharmacopoeia (USP) as a pharmaceutical excipient, there are few examples taking advantage of the unique polymer properties for use in nanomedicine applications.

Recent research and development efforts have focused on changing this, however, using PLGA not just as an inactive material but as an integral component of nanoparticle formulations that enable a wide range of nanomedicine applications, including drug targeting and delivery, imaging, immunoassays and medical devices.

To read more, please download this free white paper.

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.